Are You at High Risk of Your Melanoma Recurring?

It is important that you and your healthcare professional have the most complete picture of the risk that your melanoma may return (recur) or spread (metastasize). Important decisions such as whether a sentinel lymph node biopsy surgical procedure is appropriate for you, as well as follow-up management plans, are based on an estimate of the chances that your tumor has or will metastasize.  

MEL1

MELANOMA

MEL2

MELANOMA SPREADS TO OTHER AREAS OF THE SKIN

MEL-3

MELANOMA RETURNS OR SPREADS TO OTHER ORGANS

Traditional Approaches to Assessing Risk Levels May Lack Accuracy

Unfortunately, traditional approaches to assessing risk levels may miss patients with aggressive tumor biology. In fact, the majority of melanoma-related deaths occur in stage I or II patients thought to be low risk*

Many melanomas viewed as low risk by traditional approaches alone may actually have biology considered high risk for recurring or spreading.

Some melanomas viewed as high risk by traditional approaches alone may actually have biology considered low risk.

* Excludes stage IV patients.

SEER data release 2017; Morton et al. N EnglJ Med 2014; Whiteman et al. J Invest Dermatol 2015; Shaikh et al. J Natl Cancer Inst 2016; Poklepovic and Carvajal. Oncology 2018

Having Additional Personalized Information from DecisionDx®-Melanoma Can Help You and Your Healthcare Professional Make Better Decisions About Treating and Managing Your Melanoma

Learn How
DecisionDx®-Melanoma
Can Predict the Risk of Your Melanoma Recurring or Spreading

DecisionDXMelanomaColor.svg
Learn More

Download the Healthcare Professional Discussion Guide

MySkinMel-DiscussionGuide.png

What’s Next?

What Is DecisionDx-Melanoma?

LEARN MORE

How Do You Get a
DecisionDx-Melanoma Test?

LEARN MORE